Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder canc
- PDF / 533,761 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 139 Views
RESEARCH ARTICLE
Open Access
Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer Zhenlong Wang†, Hui Tang†, Yuquan Xue, Li Xue, Hongliang Li* and Tie Chong*
Abstract Background: Bladder cancer is the most common malignant tumor of the urinary system. One of the biological characteristics of NMIBC is the high recurrence rate after surgery. The implementation of this project aimed to investigate the role of pharmacogenomic testing-guided intravesical perfusion of chemotherapeutic agents in the postoperative perfusion therapy for non-muscle invasive bladder cancer. Method: From January 2015 to December 2016, 298 patients with non-muscle-invasive bladder cancer were enrolled in this prospective study. These patients received chemotherapy drugs after electrotherapy. According to the presence or absence of tumor susceptibility gene detection after surgery, they were divided into two groups, including the drug sensitive group(N = 44) and the control group(N = 254). The drug sensitive group received bladder infusion therapy with sensitive chemotherapy drugs based on drug sensitivity gene detection results. The control group received intravesical instillation of pirarubicin. The preoperative general data and tumor grade of patients were recorded. Cystoscopy was performed before and every 3 months after surgery. The chest CT, upper abdomen CT, renal function, and urinary routine tests were performed. Tumor recurrence, metastasis and tumorrelated death were recorded and evaluated during follow-up. Results: The drug sensitive group, which selected high-sensitivity drugs for intravesical instillation therapy based on gene expression, has a significantly lower relapse rate (11.36% vs 37.40%, P < 0.05) and a significantly longer time to relapse (17.80 ± 7.20 month vs11.20 ± 6.10 month, P < 0.05) compared with the control group. There were no significant differences in the time of mortality and death time between two groups. Conclusion: The pharmacogenomic testing-directed bladder instillation of chemotherapeutic drugs may be more effective than empiric drug administration in reducing the recurrence rate of non-muscle-invasive bladder cancer. Keywords: Non-muscle invasive bladder cancer, Pharmacogenomic testing, Chemotherapy drugs, Bladder instillation
* Correspondence: [email protected]; [email protected] † Zhenlong Wang and Hui Tang contributed equally to this work. Department of Urology, The Second Affiliated Hospital of Xi’an Jiaotong University, No.157 Xiwu Road, Xi’an 710004, Shaanxi, China © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Crea
Data Loading...
